Southport victims’ medical records wrongly accessed by 48 NHS staff in ‘unbelievable breach of privacy’ AOL.com
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
